Dentsply Sirona downgraded to Equal Weight at Morgan Stanley

As previously reported, Morgan Stanley downgraded Dentsply Sirona (XRAY) to Equal Weight from Overweight with a price target of $14, down from $21, citing sluggish innovation, share loss dynamics, tariff risk and uncertainty, and a challenging macro and dental demand backdrop. While the stock is “clearly cheap” after being the worst performer in the group in 2024 and being down 21% year-to-date, the firm views the broader outlook as uncertain given the potential tariff exposure and macro risk.